BPH Corporate [ASX: BPH] ASX Announcement 9 November 2010 Companies - PDF document

BPH Corporate [ASX: BPH] ASX Announcement 9 November 2010 Companies Announcements Office Australian Securities Exchange Limited 10 th Floor, 20 Bond Street SYDNEY NSW 2000 DR ROBIN SCAIFE TO PRESENT AT MELANOMA SYMPOSIUM TODAY BPH Corporate Limited [ASX: BPH] is pleased to attach the presentation that Principal Researcher Dr Robin Scaife has been invited by the Scott Kirkbride Melanoma Research Centre (SKMRC) to give at the Melanoma Symposium in Perth today. Dr Scaife was recently awarded a highly prestigious discovery grant which is due to start in January 2011. The SKMRC supports research that is aimed at providing crucial breakthroughs for improved diagnosis and treatment of melanomas. Dr Scaife’s presentation details innovative strategies to identify new drug leads to target melanoma cells. Although melanomas have a reputation for being particularly refractory to therapeutic intervention, some types of melanoma have recently been shown to respond well to a new class of customized cancer drugs. Dr Scaife and his collaborators at Western Australian Institute for Medical Research (WAIMR) and the University of Western Australia are using the high-content imaging and analysis platform at Molecular Discovery Systems to screen a significant new resource of new drug-like molecules for inhibitors of melanoma cell survival and proliferation. Also presenting is Dr Louise Winteringham, who as a direct result of the SKMRC grant has been leading a team at WAIMR investigating the tumor suppressor gene HLS5 and its potential influence in melanoma. Dr Winteringham said “through their research they are showing that HLS5 is targeting one of the pathways in Melanoma”. BPH has been investing in the tumor suppressor gene ‘HLS5’ project since it was reported by WAIMR Director Professor Peter Klinken in 2004. Yours sincerely, David Breeze Chairman For more information contact: Mr David Breeze, Chairman BPH Corporate Limited Tel : +61 8 9328 8366 BPH Corporate Limited ACN 95 912 002 PO Box 317, North Perth Western Australia 6906 14 View Street, North Perth Western Australia 6006 admin@biopharmica.com.au www.biopharmica.com.au T: +61 8 9328 8366 F: +61 8 9328 8733

��������������������������� ������������������������� ����� ��������������� ��������������������������� �����

� ���� ���!��� * ��������+,����������������#-%%.) ���!������� #$%&$'() "���������� Drug efflux Apoptosis "�/&0%1- � 2��3�4.%%5 #6%(����!������) ���������+,�"�������#-%$%)

������������� ��9�� ����,����������������#-%%$) ���! ��� ����! ��� 7�����������+,������������#$88.)

�������������� ���: ����& β &�������;<3"&=-2 -1 -1+' -0 -0+' ���� �� � � � ����� � � �� � � � � ����� � $8 $. $1 !��� ���� �� $% � ���� �� > 0 $ % -% 0% .% 6% $%% 9�1%�������

�����������!!��� -0+' $0+' $>+' 00 ����� ����� ����� ����� ����& β &�������;<3"&=-2 ����� �� $8 !��� �� $. � ���� �� $ ����� �������������� ���� ������� $1 !�� �� ��$ !�� �� ��- $% !�� �� ��1 > � ���� �� - !�� �� ��0 0 ���� $ 9�1%��� % -% 0% .% 6% $%% ����

������������������������� ������� �������� �������� $+- $ ��������������� %+6 %+. %+0 %+- % ������� ������� ��� <3"&=-2 ������� Apoptosis

����������4�������� <��������������+,�������������#-%%6) ����� ����� �������������+,������#-%%.)

�������������� ���� ������� ����� ���� ���&$ ���� <��������������+,������������� #-%%6)

���&����!����������� �(��!���!$)*� �� !"�� ����� �� # %"��� &�# �'� ������"��$$��� =����������+,�������������#-%%8)

=�� &����������������� �� �� # �"� � !+� '5$% Apoptosis �����������������������